

Special Issue

Diagnosis, Treatment and Prognosis of Cardiovascular Disease

Message from the Guest Editor


Cardiovascular disease represents a severe health burden, being the leading cause of morbidity and mortality worldwide. The COVID-19 pandemic has even worsened this scenario. Within these perspectives, innovative strategies of prevention, early diagnosis, and optimization of medical and non-medical therapy should be implemented. This Special Issue aims at investigating these complicated and challenging aspects, focusing on: i) innovative diagnostic tools; ii) identification of risk factors and indices of disease and prognosis; iii) risk stratification and cardiovascular prevention; iv) pharmacological and non-pharmacological therapy; v) pathophysiology and phenotypic expression of cardiovascular diseases; vi) mapping of individuals' susceptibility to cardiovascular disease; vii) cardiovascular rehabilitation; viii) models of clinical management and healthcare, with particular attention to the transfer of guideline indications to the real world.

Guest Editor

Dr. Laura Adelaide Dalla Vecchia
IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy

Deadline for manuscript submissions

closed (10 June 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed




mdpi.com/si/88631

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://jpm.mdpi.com)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).